Solopharm announces its inclusion in the list of nominees for the international «People's Choice» business award in 2026. This year, Solopharm and its brands are featured in seven nominations across two countries, reflecting the high level of trust consumers and experts have in the company's products.
Nominations in the Republic of Belarus
Within the «Medicine and Health» category, the following products are nominated:
- «Eye Moisturizing Product 2026» - Gylan
- «Vasoconstrictor Spray for Runny Nose 2026» - Oxyfrin
- «Throat Spray 2026» - Angidak
- «Respiratory Treatment Product 2026» - Angidak
- «Nasal Spray Based on Sea Water 2026» - LinAqua
Nominations in Russia
In the «Medicine and Pharmaceuticals» category, the nominations include:
- «Pharmaceutical Company of Russia 2026» - Solopharm
- «Moisturizing Eye Drops» - Gylan
About the «People's Choice» Award
From February 16 to 27, 2026, a large-scale online vote for the best goods and services will be held on the official award websites across five countries: Belarus, Russia, Kazakhstan, Kyrgyzstan, and Uzbekistan.
Winners will be determined in over 700 nominations. The vote annually attracts tens of thousands of active consumers, entrepreneurs, and experts.
You can cast your vote at the following links:
Voting for the «People's Choice» award is a direct dialogue with consumers and the professional community, providing an opportunity to affirm the quality and importance of innovative pharmaceutical solutions on an international level. User support is a key factor in building brand trust and advancing the industry as a whole.
Comment from the Solopharm Press Center
«Being nominated for the international 'People's Choice' award is a recognition of our strategy focused on innovation, quality, and safety. We are grateful to patients, the medical community, and our partners for their trust in our brands. For us, participating in the award is not only a matter of prestige but also an opportunity to hear the voice of the consumer and continue creating products that genuinely improve quality of life», stated the Solopharm press center.
